BET Bromodomain Inhibitors Enhance Efficacy and Disrupt Resistance to AR Antagonists in the Treatment of Prostate Cancer.
about
Bromodomain Inhibitor Review: Bromodomain and Extra-terminal Family Protein Inhibitors as a Potential New Therapy in Central Nervous System TumorsEpigenetic modulators as therapeutic targets in prostate cancerReplication Study: BET bromodomain inhibition as a therapeutic strategy to target c-MycBET bromodomain proteins and epigenetic regulation of inflammation: implications for type 2 diabetes and breast cancer.Exploiting Epigenetic Alterations in Prostate Cancer.Replication Study: Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia.The ETS family of oncogenic transcription factors in solid tumours.Androgen Receptor-Dependent and -Independent Mechanisms Involved in Prostate Cancer Therapy Resistance.Targeting BET bromodomain proteins in solid tumorsThe bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus.OTX015 (MK-8628), a novel BET inhibitor, exhibits antitumor activity in non-small cell and small cell lung cancer models harboring different oncogenic mutations.Androgen Receptor Deregulation Drives Bromodomain-Mediated Chromatin Alterations in Prostate Cancer.Targeting intrinsic apoptosis and other forms of cell death by BH3-mimetics in glioblastoma.Real-Time Transferrin-Based PET Detects MYC-Positive Prostate Cancer.Bromodomains in Protozoan Parasites: Evolution, Function, and Opportunities for Drug Development.Targeting persistent androgen receptor signaling in castration-resistant prostate cancer.Targeting the Breast Cancer Kinome.Androgen receptor splice variant 7 in castration-resistant prostate cancer: Clinical considerations.Kinome Profiling Identifies Druggable Targets for Novel Human Cytomegalovirus (HCMV) Antivirals.The role of glucocorticoid receptor in prostate cancer progression: from bench to bedside.Crosstalk of the Androgen Receptor with Transcriptional Collaborators: Potential Therapeutic Targets for Castration-Resistant Prostate CancerAndrogen Signaling in Prostate Cancer.Targeting Androgen Receptor Aberrations in Castration-Resistant Prostate Cancer.Targeting constitutively active androgen receptor splice variants in castration resistant prostate cancerBeyond the androgen receptor II: New approaches to understanding and treating metastatic prostate cancer; Report from the 2017 Coffey-Holden Prostate Cancer Academy Meeting.The expression of AURKA is androgen regulated in castration-resistant prostate cancer.Molecular Mechanisms of Enzalutamide Resistance in Prostate Cancer.BET inhibitors in metastatic prostate cancer: therapeutic implications and rational drug combinations.Endogenous androgen receptor proteomic profiling reveals genomic subcomplex involved in prostate tumorigenesis.Epigenetic Regulation in Prostate Cancer Progression.Mechanisms and Approaches for Overcoming Enzalutamide Resistance in Prostate Cancer.Genetics and biology of prostate cancerEnzalutamide-resistant castration-resistant prostate cancer: challenges and solutions
P2860
Q26744268-2E4299B1-69FB-4ED6-9718-24EDF13EB1F6Q28071912-623EE048-289B-4571-A927-6AB1A14FC868Q28559676-462D2FA0-3911-4E04-9D6B-8FBE6BE082F0Q30248629-A8A15A2A-7047-4496-9640-24199E5A34ACQ33755160-DE0D4EB3-6E74-4248-BD05-881544CD947AQ33842529-B5DC475A-420A-41EF-A57E-D9DCBE8130CFQ34555986-1D9F5CE6-4ED1-4E50-922A-FC9370EA1ADAQ36398998-1EB2F93F-9B37-43F6-A2FD-160F7D4BD04BQ37619860-84CCECBE-2BEC-4EFC-8A32-8AA11EE09BAEQ37702577-F5EB70C0-BA4A-480C-89E7-FC21C69738B4Q37705651-DE6EFAD7-CD83-4AEA-84E1-EC6A96C70FD0Q38673660-C11AAE07-ECE3-4B4C-84D6-D0ED6E8E00A5Q38677019-45E57D30-23B6-40DD-B2D2-EA8D36C45C0FQ38737415-E8EF618F-78EE-495E-AA6D-F14D0E8B5DA4Q38771703-79213E34-C90E-4E6D-BBBB-5936D14E0BE0Q38797560-31236ED1-AE3B-48DF-B5C2-76A18D26C626Q38836110-5315BB77-C904-4456-ACD9-E00ECF4C0FA8Q38852008-9D6AAF65-BD92-4E54-AE8A-F430D8DFB2D5Q38941812-B90B1580-72F4-49B5-9C44-8255F3D541CBQ39041932-3E3A809A-386C-49B7-8643-998EFA731473Q39164084-A16AC1E1-03A8-4D58-8EFE-4DD5E521D026Q39227656-550709C2-A7D7-4940-89C8-E0D25D679A17Q42125180-2510C5DA-FC23-4313-9B30-5D639873199BQ42182625-C2F62E0E-30A4-407E-9111-8A8CA2906431Q43578455-CF8DBDE5-1BD3-4595-A69A-25984E7171B7Q47096576-E04AA66F-A7C0-45F1-A732-B6351851D26BQ47109527-E686861A-BF0E-4724-B8A5-86BF77E041CFQ47651456-D13CF745-490E-41F1-91F2-B2324D7B5338Q50026051-31366DD2-9FB0-4294-BB5B-708B0CEC0D33Q54974720-729DEF6F-6EAF-4B3B-BA1C-FF3CB6206425Q55331819-851B61A6-F282-4C4D-9580-ED733D4CBA48Q57106917-A75365E0-5EA5-4655-832C-276C8CD512C9Q58698705-C991D755-ABEF-4167-B26C-AC39799A7410
P2860
BET Bromodomain Inhibitors Enhance Efficacy and Disrupt Resistance to AR Antagonists in the Treatment of Prostate Cancer.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
BET Bromodomain Inhibitors Enh ...... Treatment of Prostate Cancer.
@en
type
label
BET Bromodomain Inhibitors Enh ...... Treatment of Prostate Cancer.
@en
prefLabel
BET Bromodomain Inhibitors Enh ...... Treatment of Prostate Cancer.
@en
P2093
P2860
P1476
BET Bromodomain Inhibitors Enh ...... Treatment of Prostate Cancer.
@en
P2093
Arul M Chinnaiyan
Felix Y Feng
Ingrid J Apel
June Escara-Wilke
Kari Wilder-Romans
Nora M Navone
Pranathi M Krishnamurthy
Stephen R Plymate
Vijaya L Dommeti
P2860
P304
P356
10.1158/1541-7786.MCR-15-0472
P577
2016-01-20T00:00:00Z